Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 12, Pages 3566
Publisher
MDPI AG
Online
2020-11-30
DOI
10.3390/cancers12123566
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
- (2019) Luigi Formisano et al. Nature Communications
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer
- (2019) Mohamed Elbadawy et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy
- (2019) Nadiia Lypova et al. Cancers
- Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
- (2019) Sobhani et al. Cells
- MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
- (2019) Anna E. Vilgelm et al. Science Translational Medicine
- Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
- (2019) Concepción Sánchez-Martínez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Abstract PD4-01: The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER+ breast cancer
- (2018) P Mao et al. CANCER RESEARCH
- TERT regulates telomere-related senescence and apoptosis through DNA damage response in male germ cells exposed to BPDE in vitro and to B[ a ]P in vivo
- (2018) Xi Ling et al. ENVIRONMENTAL POLLUTION
- Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells
- (2018) Priyank Patel et al. MOLECULAR CANCER RESEARCH
- Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3.
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
- (2018) Jessica L.F. Teh et al. CLINICAL CANCER RESEARCH
- Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
- (2018) Kamal Pandey et al. INTERNATIONAL JOURNAL OF CANCER
- Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations
- (2018) Liqun Yu et al. CANCER LETTERS
- Differential impact of RB status on E2F1 reprogramming in human cancer
- (2017) Christopher McNair et al. JOURNAL OF CLINICAL INVESTIGATION
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition
- (2017) Míriam Tarrado‐Castellarnau et al. Molecular Systems Biology
- MYC Modulation around the CDK2/p27/SKP2 Axis
- (2017) Per Hydbring et al. Genes
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
- (2016) C Yang et al. ONCOGENE
- Ablation of human telomerase reverse transcriptase (hTERT) induces cellular senescence in gastric cancer through a galectin-3 dependent mechanism
- (2016) Sun-Hyuk La et al. Oncotarget
- A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
- (2016) Luca Malorni et al. Oncotarget
- Cdk2: a key regulator of the senescence control function of Myc
- (2016) Per Hydbring et al. Aging-US
- RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer
- (2015) Erik S Knudsen et al. CELL CYCLE
- Endocrine resistance in breast cancer – An overview and update
- (2015) Robert Clarke et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
- (2015) Christopher D. Hart et al. Nature Reviews Clinical Oncology
- Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
- (2015) Barbie Taylor-Harding et al. Oncotarget
- Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
- (2012) Jeffry L. Dean et al. CELL CYCLE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Phosphorylation Regulates c-Myc's Oncogenic Activity in the Mammary Gland
- (2011) X. Wang et al. CANCER RESEARCH
- A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
- (2011) Martin Filipits et al. CLINICAL CANCER RESEARCH
- Tipping the Balance: Cdk2 Enables Myc to Suppress Senescence
- (2010) P. Hydbring et al. CANCER RESEARCH
- Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation
- (2009) P. Hydbring et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
- (2008) Sherene Loi et al. BMC GENOMICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now